CLN-049
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 60 patients (estimated)
- Sponsors
- Cullinan Therapeutics Inc.
- Tags
- Tyrosine Kinase (TK) Inhibitor, Adoptive Cellular Therapy, FLT3 Inhibitor, CD3
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1616
- NCT Identifier
- NCT05143996
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.